DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/289ec8/dr_reddys_laborat) has announced the addition of the "Dr Reddy's Laboratories Generics Company Intelligence Report" report to their offering.
Dr Reddys is the second largest pharmaceutical manufacturer in India, behind Ranbaxy. The company sells APIs, branded drugs and generics. Most of its branded drugs are copies of drugs patented in the West, but not in India.
For the fiscal year ended 31st March 2010, Dr Reddy's reported total revenues worth Rs70,277 million (US$1,483.5 million), representing a modest increase of 1.2% over the prior year, when revenues reached Rs69,441 million. However, the firm announced profit after tax of Rs1,068 million (US$22.5 million), compared to a loss in the previous year of Rs5,168 million.
Dr Reddys is also represented in Western Europe, Russia and Asia. In 2002, the company made its first overseas acquisitions, both in the UK. In November 2005, Dr Reddys announced it had signed a definitive agreement to acquire Roches API business in Cuernavaca, Mexico. In March 2006, Dr Reddys completed its purchase of the German generic pharmaceutical firm, betapharm, from 3i, in a deal worth 480 million euros in cash. In 2007, the company announced that it was making the UK its European headquarters.
In August 2010, Dr Reddy's announced that it had launched Cresp, which it claimed was the first darbepoetin alpha copy in the world and the only one available in India. The product is a modified version of epoetin alpha, and was originally developed by Amgen in 2001
Key Topics Covered:
1. Executive Summary
4. Financial Results
5. Major Developments
6. Contact Details
For more information visit http://www.researchandmarkets.com/research/289ec8/dr_reddys_laborat
Source: Espicom Business Intelligence Ltd
Research and Markets
Laura Wood, Senior Manager,
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS: Asia Pacific India
INDUSTRY KEYWORDS: Health Pharmaceutical